Abstract

ADALIMUMAB MOSTLY PREFERABLE FOR TREATMENT OF CROHN’S DISEASE

*Patel Sunilkumar A.

Shree Krishna Institute of Pharmacy College, sankhalpur, becharaji-384210, Mehsana,India.

Abstract

Crohn's disease is a serious chronic, inflammatory disease of the gastrointestinal (GI) tract that affects more than one million people in North America and Europe. It affects people of all ages but it is primarily a disease of young adults, with onset typically before age 40.The ADALIMUMAB commonly treatment on Ulcerative colitis, polyarticular juvenile idiopathic arthritis, chronic Plaque Psoriasis, ankylosing spondylitis, psoriatics arthritis and also Rheumatoid arthritis by FDA approval but mostly preferable the by FDA approval in Crohn's disease extends the reach of ADALIMUMAB beyond rheumatology and dermatology to an underserved patient population in gastroenterology. ADALIMUMAB in more than 1,400 adult patients with moderately to severely active Crohn's disease ADALIMUMAB has been approved in 67 countries and more than 180,000 people worldwide are currently being treated with ADALIMUMAB. Onset of response was noted after 1 week of treatment. The proportions of patients attaining an ACR20 response at week 1 in the 20-mg, 40-mg, and 80-mg ADALIMUMAB dosage plus MTX groups were 26.1%, 25.4%, 31.5%, respectively.

Keywords: ADALIMUMAB, Monoclonal antibody, crohn’s disease, TNF, GIT.